Goldman Sachs downgrades Zimmer Biomet Holdings (ZBH) to a Sell
Zimmer Biomet Holdings received a Sell rating and price target from Goldman Sachs analyst David Roman today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Roman is a 3-star analyst with an average return of 2.7% and a 52.31% success rate. Roman covers the Healthcare sector, focusing on stocks such as Carlsmed, Inc., Baxter International, and Boston Scientific.
The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $101.15 average price target.
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2 billion and a net profit of $230.9 million. In comparison, last year the company earned a revenue of $1.82 billion and had a net profit of $249.1 million
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Zimmer Biomet downgraded to Sell from Neutral at Goldman Sachs
- Zimmer Biomet: Buy Rating Driven by Discounted Valuation, Lowered Expectations, and Execution Upside
- Zimmer Biomet downgraded to Market Perform from Outperform at Raymond James
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Zimmer Biomet upgraded to Outperform from In Line at Evercore ISI
